Self-appointed health authorities everywhere will be disappointed to learn that the adage "feed a cold, starve a fever" has no scientific merit. (CNN)
The National Academies have a report out on prevention of bullying.
More than a cottage industry, 3D printing of medical devices is attracting big bucks, with one California startup winning $81 million in funding. (Reuters)
Drug firm Teva announced that the company has entered the device business, via a collaboration with Intel to produce wearable monitors to track disease progression in Huntington's disease.
Continuing to toot its own horn, Teva also announced plans to launch a generic version of daptomycin (Cubicin) in the U.S.
Hand, foot, and mouth disease: Not just for little kids and their parents, as students at Florida State University in Tallahassee learned. (Tallahassee Democrat)
Authors of a review of hospital expenditures concluded that spending more on occupational therapy might actually save money. (AOTA)
Brain cancer has surpassed leukemia as the leading cause of cancer death in children, according to the CDC. (CBS News)
On the positive side, the CDC report on childhood cancers showed that mortality continues to decline. (US News and World Report)
One doc who hopes to bring a $50 EpiPen clone to market will have to traverse a rocky regulatory road. (Fortune)
Meanwhile, EpiPen maker Mylan is quietly maneuvering to secure preventive labeling for the product, a move that could eliminate out-of-pocket costs for consumers while protecting its high price. (The New York Times)
At a hearing earlier this week, purveyors of commercial cell-based therapies blasted FDA guidance suggesting the agency will regulate at least some of cell products as drugs that require regulatory approval. Here's one example. (MiMedx)
The power of positive thinking has its negative side, such as shaming depressed people. (Newsweek)
Morning Break is a daily guide to what's new and interesting on the Web for healthcare professionals, powered by the MedPage Today community. Got a tip? Send it to us: MPT_editorial@everydayhealthinc.com.